Concentrations of protease inhibitors (PIs) rose significantly with age in a study of more than 2400 people in the United Kingdom. Concentrations of nonnucleoside reverse transcriptase inhibitors (NNRTIs) and certain clinical parameters did not vary significantly with age in this analysis.
As HIV-positive people age, changes in liver function and other variables that influence drug metabolism could affect antiretroviral concentrations. To assess possible antiretroviral level changes with age, researchers analyzed data from the Liverpool TDM (therapeutic drug monitoring) Registry and linked findings with the UK Collaborative HIV Cohort (CHIC) Study. The analysis included all drug levels for PIs and NNRTIs.
The study team analyzed 3589 TDM plasma samples from 2447 antiretroviral-treated people. Most samples came from people taking lopinavir (22.4%), efavirenz (18.5%), atazanavir (17.0%) or saquinavir (11.6%).